Northland Biotech Announces Clinical Trial Approval for Brimonidine Tartrate Eye Drops

Every day AI Express, March 25th,NorthlandAnnouncement: Brimonidine Tartrate Eye Drops has received the "Drug Clinical Trial Approval Notice" (Notice No.: 2026LP00925, 2026LP00926) issued by the National Medical Products Administration, approving the initiation of clinical trials. The drug registration classification is Category 3 chemical medicine, and the applied indication is for the relief of eye redness caused by mild ocular irritation.